CORAT Therapeutics GmbH obtained regulatory authorization for clinical phase Ib/II trial with the SARS-CoV-2 neutralizing human antibody COR-101
Share this article Share this article BRAUNSCHWEIG, Germany, March 16, 2021 /PRNewswire/ -- CORAT Therapeutics GmbH obtained the regulatory approval as well as the favorable opinion from the central ethics committee to conduct the clinical phase Ib/II trial with its antibody COR-101 against COVID-19. COR-101 is a neutralizing human antibody that binds to the receptor binding domain (RBD) of the spike protein of SARS-CoV-2 and is endowed with a unique structural design. It aims to improve the treatment situation of hospitalized COVID-19 patients with moderate to severe disease, a patient group...
Source: prnewswire.com